n-(5-(2,3-dihydrobenzofuryl)sulfonyl)-n'-(3,4-dichlorophenyl)urea and Neoplasms

n-(5-(2,3-dihydrobenzofuryl)sulfonyl)-n'-(3,4-dichlorophenyl)urea has been researched along with Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Callaghan, JT; Diab, S; Forouzesh, B; Gazak, R; Goetz, A; Hammond, LA; Rowinsky, EK; Schwartz, G; Smetzer, L; Takimoto, CH; Von Hoff, DD	1

Trials

1 trial(s) available for n-(5-(2,3-dihydrobenzofuryl)sulfonyl)-n'-(3,4-dichlorophenyl)urea and Neoplasms

Article	Year
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-15, Volume: 9, Issue:15 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzofurans; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Phenylurea Compounds; Sulfonylurea Compounds; Tablets	2003

Article

Year

A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-15, Volume: 9, Issue:15

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzofurans; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Phenylurea Compounds; Sulfonylurea Compounds; Tablets

2003